Pelvic Failure Analysis in INT 0144: Evaluation of Chemotherapy Regimen, Risk Group Stratification, and Nodal Count

Stephen R. Smalley(Mayo Clinic), C. Cripps(Canadian Partnership Against Cancer), Stephen K. Williamson(The University of Kansas Cancer Center), Robert J. Mayer(Applied Natural Sciences), James A. Martenson(Mayo Clinic), J. M. Robertson(Cancer Research UK), Jacqueline Benedetti(University of Illinois Chicago), Cathryn Rankin(Cleveland Clinic), Tyvin A. Rich(The University of Texas MD Anderson Cancer Center), Angela Benson(Northwestern University)
International Journal of Radiation Oncology*Biology*Physics
August 21, 2008
10.1016/j.ijrobp.2008.06.925
Cited by 0

Related Papers

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
|JAMA|2017|891
Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection
|Journal of Clinical Oncology|2012|856
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
|Journal of Clinical Oncology|2010|840
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655